Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Nirmatrelvir and molnupiravir maintain potent in vitro and in vivo antiviral activity against circulating SARS-CoV-2 omicron subvariants.

Antiviral research - 1 Oct 2024

Rosales Romel, McGovern Briana L, Rodriguez M Luis, Leiva-Rebollo Rocio, Diaz-Tapia Randy, Benjamin Jared, Rai Devendra K, Cardin Rhonda D, Anderson Annaliesa S, Sordillo Emilia Mia, van Bakel Harm, Simon Viviana, García-Sastre Adolfo, White Kris M

Abstract excerpt

Variants of SARS-CoV-2 pose significant challenges in public health due to their increased transmissibility and ability to evade natural immunity, vaccine protection, and monoclonal antibody therapeutics. The emergence of the highly transmissible Omicron variant and subsequent subvariants, characterized by an extensive array of over 32 mutations within the spike protein, intensifies concerns regarding vaccine...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenosine Monophosphate
Share to COVID-19 Drug Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytidine

Share to Hydroxylamines

Share to Lactams

Share to Nitriles

Share to Spike Glycoprotein, Coronavirus

Share to Vero Cells

Source

Identifiers

PMID: 39067667
DOI: 10.1016/j.antiviral.2024.105970

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Nirmatrelvir and molnupiravir maintain potent in vitro and in vivo antiviral activity against circulating SARS-CoV-2 omicron subvariants.PMID 39067667Read ↗

Nirmatrelvir, Molnupiravir, and Remdesivir maintain potent <i>in vitro</i> activity against the SARS-CoV-2 Omicron variantSemantic proximity Read ↗

Evaluation of antiviral drugs against newly emerged SARS-CoV-2 Omicron subvariantsSemantic proximity Read ↗

A Detailed Overview of SARS-CoV-2 Omicron: Its Sub-Variants, Mutations and Pathophysiology, Clinical Characteristics, Immunological Landscape, Immune Escape, and Therapies.Semantic proximity Read ↗

An updated review of epidemiological characteristics, immune escape, and therapeutic advances of SARS-CoV-2 Omicron XBB.1.5 and other mutants.Semantic proximity Read ↗

Remdesivir and GS-441524 retain antiviral activity against Delta, Omicron, and other emergent SARS-CoV-2 variantsSemantic proximity Read ↗

Omicron Subvariants Infection Kinetics and Nirmatrelvir Efficacy in Transgenic K18-hACE2 MiceSemantic proximity Read ↗

Neutralization sensitivity of SARS-CoV-2 Omicron variants FL.1 and GE.1 by therapeutic antibodies and XBB sera.Semantic proximity Read ↗

Evolutionary characteristics of SARS-CoV-2 Omicron subvariants adapted to the hostSemantic proximity Read ↗

Antiviral efficacy of the SARS-CoV-2 XBB breakthrough infection sera against omicron subvariants including EG.5Semantic proximity Read ↗

The SARS-CoV-2 Omicron recombinant subvariants XBB, XBB.1, and XBB.1.5 are expanding rapidly with unique mutations, antibody evasion, and immune escape properties - an alarming global threat of a surge in COVID-19 cases again?Semantic proximity Read ↗

Neutralization escape of Omicron XBB, BR.2, and BA.2.3.20 subvariants.Semantic proximity Read ↗

Antiviral Activity of Remdesivir and Obeldesivir Against SARS-CoV-2 Omicron Subvariants That Were Circulating from September 2023 Through June 2025.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.